论文部分内容阅读
本品为白色结晶,无臭,味苦,微溶于水、醋酸乙酯、盐酸,易溶于氯仿、丙酮、乙醚、冰醋酸、二甲基甲酰胺。FD-1为继呋喃氟脲嘧啶(FT-207)之后合成的具有潜在抗癌活性的5-氟脲嘧啶(5-Fu)类衍生物。国外于1976年合成,1977年试用于临床,1978年在第十二届国际抗癌会议上介绍,其化疗指数为 FT-207的2倍,毒性为FT-207的二分之一。它与 FT-207有相同的抗肿瘤活性时其分子比为1:1.7(FD-1:FT-207)。本品对胃癌、肝癌的疗效优于 FT-207,近年来已在国内外引起广泛重视,在日本目前已进行Ⅲ期临床试用。国内已由济南制药厂研
This product is white crystal, odorless, bitter, slightly soluble in water, ethyl acetate, hydrochloric acid, soluble in chloroform, acetone, ether, glacial acetic acid, dimethylformamide. FD-1 is a 5-fluorouracil (5-Fu) derivative with potential anticancer activity synthesized after furanfluracil (FT-207). Abroad was synthesized in 1976, trial in clinical trials in 1977, introduced in the 12th International Conference on Cancer in 1978, the chemotherapy index of 2 times that of FT-207, toxicity of one-half of FT-207. It has the same antitumor activity as FT-207 at a molecular ratio of 1: 1.7 (FD-1: FT-207). The product of gastric cancer, liver cancer curative effect is superior to FT-207, in recent years has aroused widespread attention at home and abroad, in Japan has now conducted phase Ⅲ clinical trial. Domestic pharmaceutical research by Jinan Institute